Compare

Coherus Oncology, Inc. vs Tectonic Therapeutic, Inc. vs Voyager Therapeutics, Inc. vs Lexeo Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Coherus Oncology, Inc. CHRSRevenue covers only part of its income (partial revenue)	Tectonic Therapeutic, Inc. TECX	Voyager Therapeutics, Inc. VYGR	Lexeo Therapeutics, Inc. LXEO
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	$40.37M	n/a
Revenue growth (YoY)	n/a	n/a	-49.5%	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	-326.6%	n/a
Net margin	n/a	n/a	-296.5%	n/a
Net income	$168.02M	-$74.15M	-$119.72M	-$99.96M
EPS (Diluted)	$1.43	-$4.05	-$2.04	-$1.86
Operating cash flow	-$138.51M	-$60.08M	-$132.47M	-$98.56M
Free cash flow	n/a	-$60.29M	-$135.06M	-$98.96M
Cash & equivalents	$88.88M	$253.80M	$65.30M	$63.00M
Total assets	$258.34M	$261.04M	$252.28M	$268.69M
Total liabilities	$197.33M	$9.71M	$56.20M	$22.02M
Shareholders' equity	$61.01M	$251.33M	$196.08M	$246.67M
Return on year-end equity	275.4%	-29.5%	-61.1%	-40.5%
Shares outstanding	121.15M	18.74M	59.05M	73.00M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Coherus Oncology, Inc.	Tectonic Therapeutic, Inc.	Voyager Therapeutics, Inc.	Lexeo Therapeutics, Inc.
Latest	n/a	n/a	$40.37M Ended 2025-12-31	$654.0K Ended 2022-12-31
1 year earlier	n/a	n/a	$80.00M Ended 2024-12-31	n/a
2 years earlier	n/a	n/a	$250.01M Ended 2023-12-31	n/a
3 years earlier	n/a	n/a	$40.91M Ended 2022-12-31	n/a
4 years earlier	n/a	n/a	$37.41M Ended 2021-12-31	n/a